Table 1.
Variable | CVH | NAFLD | CVH with ESRD | CVH without ESRD | NAFLD with inactive HBsAg carrier | NAFLD without inactive HBsAg carrier | Total |
---|---|---|---|---|---|---|---|
N | 15 | 17 | 8 | 7 | 6 | 11 | 32 |
Age (Y) | 38.07 ± 12.74 | 38.71 ± 9.02 | 41.25 ± 11.79 | 34.43 ± 13.70 | 35.67 ± 12.011 | 40.36 ± 7.03 | 38.41 ± 10.74 |
Sex (M/F) | 11/4 | 12/5 | 6/2 | 5/2 | 6/0 | 6/5 | 23/9 |
ElastPQ (Average) (kPa) | 5.52 (4.74–7.48) | 5.92 (4.58–6.46) | 5.29 (4.78–9.00) | 6.21 (5.68–7.28) | 4.58 (3.30–5.92) | 5.10 (4.78–10.06) | 5.29 (4.69–9.40) |
ElastPQ (Median) (kPa) | 5.54 (4.63–7.20) | 5.72 (4.67–6.28) | 5.09 (4.62–9.14) | 6.16 (5.67–7.03) | 4.67 (3.55–5.84) | 4.92 (4.52–9.60) | 5.12 (4.61–9.18) |
TE (Median) (kPa) | 9.0 (5.7–11.9) | 7.8 (5.7–13.5) | 9.2 (5.6–11.2) | 12.8 (9.3–15.2) | 5.7 (4.7–5.8) | 7.3 (5.0–13.3) | 9.4 (6.1–11.6) |
Fibrosis stage | |||||||
F0 | 4 (26.7%) | 6 (35.3%) | 0 (0%) | 4 (57.1%) | 4 (66.7%) | 2 (18.2%) | 10 (31.3%) |
F1 | 8 (53.3%) | 4 (23.5%) | 6 (75%) | 2 (28.6%) | 0 (0%) | 4 (36.4%) | 12 (37.5%) |
F2 | 2 (13.3%) | 3 (17.7%) | 1 (12.5%) | 1 (14.3%) | 1 (16.7%) | 2 (18.2%) | 5 (15.6%) |
F3 | 1 (6.7%) | 1 (5.9%) | 1 (12.5%) | 0 (0%) | 0 (0%) | 1 (9.1%) | 2 (6.3%) |
F4 | 0 (0%) | 3 (17.6%) | 0 (0%) | 0 (0%) | 1 (16.7%) | 2 (18.2%) | 3 (9.4%) |
CVH, chronic viral hepatitis; NAFLD, nonalcoholic fatty liver disease; ESRD, end-stage renal disease; TE, transient elastography.